JIR
ITOS

James Investment Research’s iTeos Therapeutics ITOS Stock Holding History

James Investment Research’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,680
Closed -$36K – 404
2023
Q1 		$36K Buy
+2,680
New +$48K ﹤0.01% 387

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

James Investment Research's ITOS Position: Q2 2023 in Review

James Investment Research sold out of iTeos Therapeutics (ITOS) in Q2 2023, closing a stake of 2,680 shares — an estimated $36K sold.

James Investment Research first reported a position in ITOS in Q1 2023 and held it in 1 quarter. The position peaked at $36K in Q1 2023. 146 funds tracked by Wall St. Rank hold ITOS as of Q2 2023.

  • James Investment Research reported no remaining iTeos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • James Investment Research sold 2,680 iTeos Therapeutics shares in Q2 2023, an estimated $36K.
  • James Investment Research first reported a position in iTeos Therapeutics in Q1 2023 and held it in 1 quarter.
  • James Investment Research's iTeos Therapeutics position peaked at $36K in Q1 2023.
  • 146 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2023.

Based on James Investment Research's 13F filing for Q2 2023, filed 7 Aug 2023.